^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER negative

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2d
    Sentinel lymph node biopsy using dye alone in patients with initial clinical N1 breast cancer receiving neoadjuvant therapy: A multicenter diagnostic trial (Northern Breast Cancer Collaboration Group NBCG-002). (PubMed, Cancer)
    Single-dye SLNB after NAT in patients initially diagnosed with cN1 breast cancer yielded a clinically acceptable FNR. When four or more SLNs were identified, an additional benefit was observed in patients who had a BMI <25 kg/m2 and negative estrogen receptor status.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HR negative • ER negative • EGFR positive
    3d
    Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC (clinicaltrials.gov)
    P1, N=20, Recruiting, Baylor Research Institute | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor)
    |
    ER negative
    |
    Keytruda (pembrolizumab) • cisplatin • bortezomib
    4d
    Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P=N/A, N=225, Recruiting, University Hospital Tuebingen | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    4d
    POLARIS: Adjuvant Intensification for LAR (clinicaltrials.gov)
    P3, N=904, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    everolimus
    5d
    Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer. (PubMed, Breast Cancer Res Treat)
    PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.
    Retrospective data • Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative • ER negative
    5d
    ESPRESSOBREAST: Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers (clinicaltrials.gov)
    P=N/A, N=1050, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 overexpression • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 positive + HER-2 overexpression
    5d
    Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=416, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    7d
    Overall Survival in Breast Cancer Patients: Analysis of a 27-Year Historical Cohort. (PubMed, Asian Pac J Cancer Prev)
    During the study period, the overall survival rate in this cohort of women with breast cancer was 83.1% at five years and 65.5% at ten years. Different clinical, biological and tumor-related factors significantly affected prognosis in this population.
    Retrospective data • Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    9d
    Citrate silver nanoparticles modulate estrogen signaling in estradiol-supplemented ER-positive breast cancer cells. (PubMed, Mol Cell Endocrinol)
    Our results suggest that the surface chemistry of silver nanoparticles may facilitate their ability to modulate estrogen signaling and interact with the estrogen receptor. Furthermore, the nanoplastics pollution may influence the cytotoxicity of silver nanoparticles. This paper highlights the importance of endocrine research in breast cancer, particularly within the context of nanoplastics pollution and the use of nanotechnology in breast cancer treatment.
    Journal
    |
    ER (Estrogen receptor) • CAV1 (Caveolin 1) • GPER1 (G Protein-Coupled Estrogen Receptor 1)
    |
    ER positive • ER negative
    9d
    Integrating molecular classification into endometrial cancer management. (PubMed, Eur J Surg Oncol)
    We also discussed implementation challenges, including test standardization, reporting, equity of access, and areas of ongoing uncertainty. This position paper aims to support consistent, equitable, and biologically informed management of endometrial carcinoma in contemporary practice.
    Review • Journal
    |
    ER (Estrogen receptor) • MSI (Microsatellite instability)
    |
    ER positive • MSI-H/dMMR • ER negative
    10d
    Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (clinicaltrials.gov)
    P3, N=1978, Not yet recruiting, National Cancer Institute (NCI)
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • letrozole • anastrozole • exemestane
    10d
    SKYLINE: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PD-L1 negative • ER negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • tiragolumab (RG6058)